Biogen Joins Target Validation Group
Biogen has joined the Center for Therapeutic Target Validation (CTTV), a public-private collaboration to improve the success rate for discovering new medicines. Originally formed by GlaxoSmithKline (GSK) the Wellcome Trust Sanger Institute, and the European Bioinformatics Institute (EMBL-EBI), the CTTV fosters ongoing interactions between academic and industry members for the purpose of developing open, approaches to selecting and validating novel targets in drug development.
Biogen's new membership follows the launch of the new CTTV Target Validation Platform, which helps researchers identify therapeutic targets for new medicines. The platform has had over 9000 visits since its launch in December 2015.
The CTTV uses advances in genetic research and computational biology in drug discovery and development.Target validation, an exercise that clearly defines the role that a biological process plays in a disease, is a key initial phase of drug discovery. Currently, an estimated 90% of compounds entering clinical trials fail to demonstrate the necessary efficacy and safety requirements often because the biological target chosen is not well understood.